Glaxosmithkline Consumer Healthcare Holdings DBA Haleon: Drug Recall

Recall #D-0183-2023 · 12/06/2022

Class I: Dangerous

Recall Details

Recall Number: D-0183-2023
Classification: Class I
Product Type: Drug
Recalling Firm: Glaxosmithkline Consumer Healthcare Holdings DBA Haleon
Status: Terminated
Date Initiated: 12/06/2022
Location: Warren, NJ, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 209,292 capsules

Reason for Recall

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Product Description

Advil Liqui Gels (minis), Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Pfizer, Madison, NJ 07940, UPC 3 0573 1769 13 5

Distribution Pattern

Nationwide in the USA.

Other Recalls by Glaxosmithkline Consumer Healthcare Holdings DBA Haleon

Class I: Dangerous 12/06/2022

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back
Class I: Dangerous 12/06/2022

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

View all recalls by Glaxosmithkline Consumer Healthcare Holdings DBA Haleon →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.